# 💊 WIA-BIO-009: Drug Discovery Standard

[![Version](https://img.shields.io/badge/version-1.0.0-blue.svg)]()
[![License](https://img.shields.io/badge/license-MIT-green.svg)]()
[![Standard](https://img.shields.io/badge/WIA-Standard-purple.svg)]()


> **Standard ID:** WIA-BIO-009
> **Version:** 1.0.0
> **Status:** Active
> **Category:** BIO / Biotechnology & Life Sciences
> **Color:** Teal (#14B8A6)

---

## 🌟 Overview

The WIA-BIO-009 standard defines a comprehensive framework for drug discovery processes, from target identification through clinical trials. It provides standardized methods for compound screening, lead optimization, ADMET prediction, and regulatory submission.

**홍익인간 (弘益人間) - Benefit All Humanity** - This standard aims to accelerate drug discovery and make life-saving medicines accessible to all through open, transparent, and standardized processes.

## 🎯 Key Features

- **Target Identification & Validation**: Systematic approaches for identifying disease targets
- **High-Throughput Screening (HTS)**: Automated compound screening protocols
- **Lead Optimization**: Medicinal chemistry strategies for improving candidates
- **ADMET Prediction**: Computational models for absorption, distribution, metabolism, excretion, and toxicity
- **Preclinical Studies**: Standardized protocols for in vitro and in vivo testing
- **Clinical Trial Management**: Data standards for Phase I-IV trials
- **Regulatory Compliance**: Frameworks for FDA, EMA, and global submissions

## 📊 Core Concepts

### 1. Inhibitory Concentration (IC50)

```
IC50 = concentration at 50% inhibition
```

Where:
- `IC50` = Half maximal inhibitory concentration
- Lower IC50 = More potent compound
- Typical range: 1 nM - 100 μM

### 2. Binding Affinity (Ki)

```
Ki = [E][I] / [EI]
```

Where:
- `Ki` = Inhibition constant
- `[E]` = Free enzyme concentration
- `[I]` = Free inhibitor concentration
- `[EI]` = Enzyme-inhibitor complex

### 3. Lipophilicity (LogP)

```
LogP = log10(Poctanol/water)
```

Where:
- `LogP` = Partition coefficient
- Optimal range: 0-3 for drug-likeness
- Higher LogP = More lipophilic

### 4. Oral Bioavailability (F)

```
F = (AUCoral × Doseiv) / (AUCiv × Doseoral) × 100%
```

Where:
- `F` = Bioavailability percentage
- `AUC` = Area under curve
- Target: F > 30% for oral drugs

## 🔧 Components

### TypeScript SDK

```typescript
import {
  DrugDiscoverySDK,
  screenCompounds,
  optimizeLead,
  predictADMET
} from '@wia/bio-009';

// Screen compound library
const results = await screenCompounds({
  target: 'EGFR kinase',
  library: compoundLibrary,
  assayType: 'binding',
  threshold: { ic50: 1e-6 } // 1 μM
});

// Optimize lead compound
const optimized = optimizeLead({
  compound: leadCompound,
  objectives: ['potency', 'solubility', 'safety'],
  constraints: {
    mw: { max: 500 },
    logP: { min: 0, max: 3 }
  }
});

// Predict ADMET properties
const admet = predictADMET({
  smiles: 'CC(C)Cc1ccc(cc1)C(C)C(=O)O',
  models: ['solubility', 'permeability', 'hERG', 'cyp450']
});

console.log(admet.bioavailability, admet.toxicityRisk);
```

### CLI Tool

```bash
# Screen compound library
wia-bio-009 screen --target "EGFR" --library compounds.sdf --ic50-max 1e-6

# Optimize lead compound
wia-bio-009 optimize --smiles "CC(=O)Oc1ccccc1C(=O)O" --property potency

# Predict ADMET profile
wia-bio-009 predict-admet --smiles "CN1C=NC2=C1C(=O)N(C(=O)N2C)C"

# Generate regulatory dossier
wia-bio-009 generate-dossier --compound-id WIA-001 --phase "Phase-II"

# Assess safety profile
wia-bio-009 assess-safety --data toxicity-data.json --species rat
```

## 📚 Documentation

| Document | Description |
|----------|-------------|
| [WIA-BIO-009-v1.0.md](./spec/WIA-BIO-009-v1.0.md) | Complete specification with protocols |
| [TypeScript SDK](./api/typescript/) | Full TypeScript implementation |
| [CLI Tool](./cli/wia-bio-009.sh) | Command-line interface |

## 🚀 Quick Start

### Installation

```bash
# Clone repository
git clone https://github.com/WIA-Official/wia-standards.git
cd wia-standards/standards/drug-discovery

# Run installation script
./install.sh

# Verify installation
wia-bio-009 --version
```

### TypeScript Usage

```bash
# Install via npm
npm install @wia/bio-009

# Or yarn
yarn add @wia/bio-009
```

```typescript
import { DrugDiscoverySDK } from '@wia/bio-009';

const sdk = new DrugDiscoverySDK();

// Screen compounds against target
const screening = sdk.screenCompounds({
  target: {
    name: 'EGFR',
    type: 'kinase',
    species: 'human'
  },
  compounds: [
    { id: 'CPD-001', smiles: 'CC(C)Cc1ccc(cc1)C(C)C(=O)O' },
    { id: 'CPD-002', smiles: 'CC(=O)Oc1ccccc1C(=O)O' }
  ],
  assayType: 'enzymatic'
});

console.log(`Found ${screening.hits.length} hits`);
console.log(`Best IC50: ${screening.hits[0].ic50} M`);
```

## 🔬 Drug Discovery Pipeline

| Stage | Duration | Success Rate | Key Metrics |
|-------|----------|--------------|-------------|
| Target Identification | 2-3 years | 100% | Validation score |
| Hit Discovery | 3-6 months | 1-5% | Hit rate |
| Lead Optimization | 1-2 years | 10-20% | IC50, LogP, F% |
| Preclinical | 1-2 years | 30% | LD50, PK/PD |
| Phase I | 1-2 years | 70% | Safety, MTD |
| Phase II | 2-3 years | 33% | Efficacy |
| Phase III | 2-4 years | 25-30% | P-value |
| FDA Approval | 1-2 years | 90% | NDA/BLA |

## 🧪 Lipinski's Rule of Five

For oral bioavailability, compounds should satisfy:

1. **Molecular Weight** ≤ 500 Da
2. **LogP** ≤ 5
3. **H-bond Donors** ≤ 5
4. **H-bond Acceptors** ≤ 10

```typescript
const isLipinskiCompliant = sdk.checkLipinski({
  mw: 450,
  logP: 2.5,
  hbd: 3,
  hba: 6
});
// Returns: { compliant: true, violations: [] }
```

## ⚠️ Safety Considerations

1. **Toxicity Testing**: All compounds must pass Ames test, hERG assay, and CYP450 inhibition
2. **Animal Welfare**: Follow 3Rs principles (Replace, Reduce, Refine)
3. **Dose Limits**: Maximum tolerated dose (MTD) determination required
4. **Genotoxicity**: ICH M7 guidelines for DNA-reactive impurities
5. **Reproductive Toxicity**: ICH S5 guidelines for fertility studies

## 🌐 WIA Integration

This standard integrates with:
- **WIA-INTENT**: Natural language drug discovery queries
- **WIA-OMNI-API**: Universal API for drug databases
- **WIA-CHEM**: Chemical structure standards
- **WIA-CLINICAL**: Clinical trial data standards
- **WIA-GENOMICS**: Target genomics integration

## 📖 Use Cases

1. **Small Molecule Drugs**: Traditional pharmaceutical development
2. **Biologics**: Antibodies, proteins, and peptides
3. **Vaccines**: Preventive and therapeutic vaccines
4. **Drug Repurposing**: Finding new uses for existing drugs
5. **Personalized Medicine**: Patient-specific drug optimization
6. **Rare Diseases**: Orphan drug development
7. **Combination Therapy**: Synergistic drug combinations
8. **Antibiotic Discovery**: Combating antimicrobial resistance

## 🤝 Contributing

Contributions welcome! Please see our [Contributing Guide](https://github.com/WIA-Official/wia-standards/CONTRIBUTING.md).

## 📄 License

MIT License - see [LICENSE](https://github.com/WIA-Official/wia-standards/LICENSE)

## 🔗 Links

- **Website**: [wiastandards.com](https://wiastandards.com)
- **GitHub**: [github.com/WIA-Official/wia-standards](https://github.com/WIA-Official/wia-standards)
- **Documentation**: [docs.wiastandards.com](https://docs.wiastandards.com)
- **Certification**: [cert.wiastandards.com](https://cert.wiastandards.com)

---

**홍익인간 (弘益人間) · Benefit All Humanity**

*WIA - World Certification Industry Association*
*© 2025 SmileStory Inc. / WIA*
*MIT License*

---

**홍익인간 (弘益人間) - Benefit All Humanity** 🌍
